Pacira BioSciences, Inc. (NASDAQ:PCRX) Receives Average Rating of “Hold” from Analysts

Shares of Pacira BioSciences, Inc. (NASDAQ:PCRX) have earned an average rating of “Hold” from the ten ratings firms that are presently covering the firm, MarketBeat.com reports. Two analysts have rated the stock with a sell rating, four have issued a hold rating and four have assigned a buy rating to the company. The average 12-month target price among brokers that have updated their coverage on the stock in the last year is $23.50.

A number of analysts recently weighed in on the stock. HC Wainwright restated a “buy” rating and set a $39.00 target price on shares of Pacira BioSciences in a research note on Wednesday, December 4th. Needham & Company LLC reissued a “buy” rating and issued a $22.00 price objective on shares of Pacira BioSciences in a research report on Friday, November 8th. Jefferies Financial Group raised their price objective on shares of Pacira BioSciences from $15.00 to $18.00 and gave the company a “buy” rating in a report on Tuesday, September 24th. Royal Bank of Canada boosted their target price on shares of Pacira BioSciences from $15.00 to $16.00 and gave the stock a “sector perform” rating in a research note on Thursday, November 7th. Finally, Barclays cut their price target on Pacira BioSciences from $25.00 to $17.00 and set an “equal weight” rating on the stock in a research note on Tuesday, November 12th.

Institutional Trading of Pacira BioSciences

Hedge funds and other institutional investors have recently made changes to their positions in the company. Dimensional Fund Advisors LP boosted its position in shares of Pacira BioSciences by 12.2% in the 2nd quarter. Dimensional Fund Advisors LP now owns 1,828,065 shares of the company’s stock valued at $52,300,000 after purchasing an additional 198,936 shares during the period. Pacer Advisors Inc. boosted its holdings in shares of Pacira BioSciences by 129.4% in the third quarter. Pacer Advisors Inc. now owns 4,962,221 shares of the company’s stock valued at $74,681,000 after acquiring an additional 2,799,434 shares during the period. WINTON GROUP Ltd acquired a new stake in shares of Pacira BioSciences in the second quarter valued at approximately $2,726,000. Banco Santander S.A. acquired a new position in shares of Pacira BioSciences in the 2nd quarter valued at $3,959,000. Finally, BNP Paribas Financial Markets raised its position in Pacira BioSciences by 269.7% in the 3rd quarter. BNP Paribas Financial Markets now owns 395,695 shares of the company’s stock valued at $5,955,000 after purchasing an additional 288,662 shares during the last quarter. Institutional investors and hedge funds own 99.73% of the company’s stock.

Pacira BioSciences Price Performance

Shares of NASDAQ PCRX opened at $19.65 on Wednesday. The company has a debt-to-equity ratio of 0.51, a current ratio of 2.25 and a quick ratio of 1.89. The company has a market cap of $907.30 million, a price-to-earnings ratio of -9.68 and a beta of 0.80. The stock’s 50-day moving average is $17.91 and its two-hundred day moving average is $18.25. Pacira BioSciences has a 1-year low of $11.16 and a 1-year high of $35.95.

About Pacira BioSciences

Pacira Biosciences, Inc is a holding company, which engages in the provision of non-opioid pain management and regenerative health solutions to improve patients’ journeys along the neural pain pathway. Its products include EXPAREL, iovera, and DepoFoam. The company was founded in December 2006 and is headquartered in Tampa, FL.